Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (BRV) are pyrrolidone derivate compounds binding at the presynaptic SV2A receptor site and are thus representative of AEDs with a unique mode of action. LEV was extensively investigated in randomized controlled trials and has a very promising efficacy both in focal and generalized epilepsies. Its pharmacokinetic profile is favorable and LEV does not undergo clinically relevant interactions. Adverse reactions comprise mainly asthenia, somnolence, and behavioral symptoms. It has now been established as a first-line antiepileptic drug. BRV has been recently introduced as an adjunct antiepileptic drug in focal epilepsy with a similarly promising pharmacokinetic profile and possibly increased tolerability concerning psychiatric adverse events. This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Clinically, both levetiracetam and brivaracetam have favorable safety, simple kinetics, and flexible dosing that support long-term administration [224,225].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [225]
The cited source says what the claim attributes to it.
In the citing paper
“Brivaracetam may show improved behavioral tolerability in some patients, and switching within the class is feasible when adverse effects emerge, enabling continuity of presynaptic stabilization [219,225].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Jasper's Basic Mechanisms of the Epilepsies
(2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.001.0001 · Cited by 1,143
Antiepileptic Drug Mechanisms of Action
Macdonald, R. L., & Kelly, K. M. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb05996.x · Cited by 591
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Perucca, E., Sabers, A., Thomas, S. V., Vajda, F., Faravelli, F., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30107-8 · Cited by 544
Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group (2000) · Neurology · doi:10.1212/wnl.55.2.236 · Cited by 524
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506
Clinical Pharmacokinetics of Levetiracetam
Patsalos, P. N. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00002 · Cited by 473
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Brodie, M. J., Perucca, E., Ryvlin, P., Ben-Menachem, E., & Meencke, H.-J. (2007) · Neurology · doi:10.1212/01.wnl.0000252941.50833.4a · Cited by 467
Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., & for the European Levetiracetam Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00323.x · Cited by 451
Ben‐Menachem, E., & Falter, U. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb04605.x · Cited by 409
Selective Blockade of N‐Type Calcium Channels by Levetiracetam
Lukyanetz, E. A., Shkryl, V. M., & Kostyuk, P. G. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.24501.x · Cited by 338
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Piracetam: A Review of Pharmacological Properties and Clinical Uses
Winblad, B. (2005) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00268.x · Cited by 317
Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review
Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P., & Steinhoff, B. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012021 · Cited by 288
Self-citationLöscher, W., & Hönack, D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90768-d · Cited by 281
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy
Berkovic, S. F., Knowlton, R. C., Leroy, R. F., Schiemann, J., & Falter, U. (2007) · Neurology · doi:10.1212/01.wnl.0000268699.34614.d3 · Cited by 257
Noyer, M., Gillard, M., Matagne, A., Hénichart, J.-P., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255
Biton, V., Berkovic, S. F., Abou‐Khalil, B., Sperling, M. R., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12433 · Cited by 253
Gillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
Noachtar, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W. B., & Schiemann-Delgado, J. (2008) · Neurology · doi:10.1212/01.wnl.0000297512.18364.40 · Cited by 242
Klein, P., Schiemann, J., Sperling, M. R., Whitesides, J., Liang, W., Stalvey, T., Brandt, C., & Kwan, P. (2015) · Epilepsia · doi:10.1111/epi.13212 · Cited by 239
Ryvlin, P., Werhahn, K. J., Blaszczyk, B., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12432 · Cited by 231
Betts, T., Waegemans, T., & Crawford, P. (2000) · Seizure · doi:10.1053/seiz.2000.0380 · Cited by 230
Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030913e · Cited by 226
Matagne, A., Margineanu, D., Kenda, B., Michel, P., & Klitgaard, H. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.198 · Cited by 224
Niespodziany, I., Klitgaard, H., & Margineanu, D. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01884-5 · Cited by 220
Yasiry, Z., & Shorvon, S. D. (2014) · Seizure · doi:10.1016/j.seizure.2013.12.007 · Cited by 209
Patsalos, P. N. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0087-0 · Cited by 184
Kasteleijn-Nolst Trenité, D. G. A., Marescaux, C., Stodieck, S., Edelbroek, P. M., & Oosting, J. (1996) · Epilepsy Research · doi:10.1016/s0920-1211(96)00031-9 · Cited by 183
Werhahn, K. J., Trinka, E., Dobesberger, J., Unterberger, I., Baum, P., Deckert‐Schmitz, M., Kniess, T., Schmitz, B., Bernedo, V., Ruckes, C., et al. (2015) · Epilepsia · doi:10.1111/epi.12926 · Cited by 177
Kaminski, R. M., Matagne, A., Leclercq, K., Gillard, M., Michel, P., Kenda, B., Talaga, P., & Klitgaard, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.11.021 · Cited by 169
Nicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Kwan, P., Trinka, E., Van Paesschen, W., Rektor, I., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12391 · Cited by 164
Comparative retention rates and long-term tolerability of new antiepileptic drugs
Chung, S., Wang, N., & Hank, N. (2007) · Seizure · doi:10.1016/j.seizure.2007.01.004 · Cited by 161
Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open‐label Trial
Glauser, T. A., Pellock, J. M., Bebin, E. M., Fountain, N. B., Ritter, F. J., Jensen, C. M., & Shields, W. D. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13101.x · Cited by 160
Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial
French, J. A., Costantini, C., Brodsky, A., & von Rosenstiel, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ec7f7f · Cited by 158
Yates, S. L., Fakhoury, T., Liang, W., Eckhardt, K., Borghs, S., & D'Souza, J. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.09.005 · Cited by 155
Kellinghaus, C., Rossetti, A. O., Trinka, E., Lang, N., May, T. W., Unterberger, I., Rüegg, S. J., Sutter, R., Strzelczyk, A., Tilz, C., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25416 · Cited by 150
Van Paesschen, W., Hirsch, E., Johnson, M., Falter, U., & von Rosenstiel, P. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03598.x · Cited by 141
Sargentini‐Maier, M. L., Rolan, P., Connell, J., Tytgat, D., Jacobs, T., Pigeolet, E., Riethuisen, J., & Stockis, A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02829.x · Cited by 141
Safety Profile of Levetiracetam
Harden, C. L. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00008.x · Cited by 138
Navarro, V., Dagron, C., Elie, C., Lamhaut, L., Demeret, S., Urien, S., An, K., Bolgert, F., Tréluyer, J., Baulac, M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00296-3 · Cited by 137
Giurgea, C. E., & Salama, M. (1977) · Progress in Neuro-Psychopharmacology · doi:10.1016/0364-7722(77)90046-7 · Cited by 134
Vogl, C., Mochida, S., Wolff, C., Whalley, B. J., & Stephens, G. J. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076687 · Cited by 132
Long-term continuation of levetiracetam in patients with refractory epilepsy
Krakow, K., Walker, M., Otoul, C., & Sander, J. W. A. S. (2001) · Neurology · doi:10.1212/wnl.56.12.1772 · Cited by 128
Genton, P., & Van Vleymen, B. (2000) · Epileptic Disorders · doi:10.1684/j.1950-6945.2000.tb00363.x · Cited by 124
Rolan, P., Sargentini‐Maier, M. L., Pigeolet, E., & Stockis, A. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03158.x · Cited by 124
Trinka, E., Marson, A. G., Van Paesschen, W., Kälviäinen, R., Marovac, J., Duncan, B., Buyle, S., Hallström, Y., Hon, P., Muscas, G. C., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300376 · Cited by 121
Kaminski, R. M., Gillard, M., Leclercq, K., Hanon, E., Lorent, G., Dassesse, D., Matagne, A., & Klitgaard, H. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02089.x · Cited by 116
A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus
Frucht, S. J., Louis, E. D., Chuang, C., & Fahn, S. (2001) · Neurology · doi:10.1212/wnl.57.6.1112 · Cited by 115
Perucca, E., Gidal, B. E., & Baltes, E. (2003) · Epilepsy Research · doi:10.1016/s0920-1211(02)00250-4 · Cited by 115
Steinig, I., von Podewils, F., Möddel, G., Bauer, S., Klein, K. M., Paule, E., Reif, P. S., Willems, L. M., Zöllner, J. P., Kunz, R., et al. (2017) · Epilepsia · doi:10.1111/epi.13768 · Cited by 115
Patsalos, P. N. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0088-z · Cited by 111
Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
Trenité, D. G. A. K.-N., Genton, P., Parain, D., Masnou, P., Steinhoff, B. J., Jacobs, T., Pigeolet, E., Stockis, A., & Hirsch, É. (2007) · Neurology · doi:10.1212/01.wnl.0000271385.85302.55 · Cited by 111
Self-citationSerum Concentrations of Levetiracetam in Epileptic Patients: The Influence of Dose and Co-medication
May, T. W., Rambeck, B., & rgens, U. J. (2003) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200312000-00007 · Cited by 110
Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant Drug
De Smedt, T., Raedt, R., Vonck, K., & Boon, P. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00005.x · Cited by 104
Magaudda, A., Gélisse, P., & Genton, P. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.56902.x · Cited by 102
Mundlamuri, R. C., Sinha, S., Subbakrishna, D. K., Prathyusha, P. V., Nagappa, M., Bindu, P. S., Taly, A. B., Rao, G. S. U., & Satishchandra, P. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.04.013 · Cited by 101
Wood, M. D., & Gillard, M. (2017) · Epilepsia · doi:10.1111/epi.13638 · Cited by 101
Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam
Krauss, G. L., Bergin, A. M. R., Kramer, R. E., Cho, Y.-W., & Reich, S. G. (2001) · Neurology · doi:10.1212/wnl.56.3.411 · Cited by 101
Morrell, M. J., Leppik, I. E., French, J. A., Ferrendelli, J. A., Han, J. Y., & Magnus, L. (2003) · Epilepsy Research · doi:10.1016/s0920-1211(03)00080-9 · Cited by 100
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
Antimyoclonic effect of levetiracetam
Genton, P., & Gélisse, P. (2000) · Epileptic Disorders · doi:10.1684/j.1950-6945.2000.tb00445.x · Cited by 96
Levetiracetam versus phenytoin in management of status epilepticus
Chakravarthi, S., Goyal, M., Modi, M., Bhalla, A., & Singh, P. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.12.013 · Cited by 95
Effectiveness of piracetam in cortical myoclonus
Brown, P., Steiger, M. J., Thompson, P. D., Rothwell, J. C., Day, B. L., Salama, M., Waegemans, T., & Marsden, C. D. (1993) · Movement Disorders · doi:10.1002/mds.870080112 · Cited by 93
Strzelczyk, A., Kay, L., Bauer, S., Immisch, I., Klein, K. M., Knake, S., Kowski, A. B., Kunz, R., Kurlemann, G., Langenbruch, L. M., et al. (2018) · Epilepsia · doi:10.1111/epi.14476 · Cited by 85
Self-citationStrzelczyk, A., Steinig, I., Willems, L. M., Reif, P. S., Senft, C., Voß, M., Gaida, B., von Podewils, F., & Rosenow, F. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.03.028 · Cited by 84
Villanueva, V., López-González, F. J., Mauri, J. A., Rodriguez-Uranga, J., Olivé-Gadea, M., Montoya, J., Ruiz-Giménez, J., Zurita, J., & the BRIVA-LIFE study group (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13059 · Cited by 84
Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam
Genton, P., & Gélisse, P. (2001) · Neurology · doi:10.1212/wnl.57.6.1144-b · Cited by 82
Hirsch, M., Hintz, M., Specht, A., & Schulze-Bonhage, A. (2018) · Seizure · doi:10.1016/j.seizure.2018.07.017 · Cited by 82
Fattore, C., Boniver, C., Capovilla, G., Cerminara, C., Citterio, A., Coppola, G., Costa, P., Darra, F., Vecchi, M., & Perucca, E. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02976.x · Cited by 81
Labiner, D. M., Ettinger, A. B., Fakhoury, T. A., Chung, S. S., Shneker, B. F., Tatum, W. O., Miller, J. M., Vuong, A., Hammer, A. E., & Messenheimer, J. A. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01792.x · Cited by 78
Steinhoff, B. J., Bacher, M., Bucurenciu, I., Hillenbrand, B., Intravooth, T., Kornmeier, R., Kurth, C., Stockinger, J., & Staack, A. M. (2017) · Seizure · doi:10.1016/j.seizure.2017.03.010 · Cited by 76
Self-citationSpotlight on Levetiracetam in Epilepsy†
Lyseng-Williamson, K. A. (2011) · CNS Drugs · doi:10.2165/11208340-000000000-00000 · Cited by 73
Effect of levetiracetam on human corticospinal excitability
Sohn, Y. H., Kaelin‐Lang, A., Jung, H. Y., & Hallett, M. (2001) · Neurology · doi:10.1212/wnl.57.5.858 · Cited by 72
The pharmacokinetic characteristics of levetiracetam
Patsalos, P. N. (2003) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2003.25.2.723686 · Cited by 71
Levetiracetam treatment of idiopathic generalised epilepsy
Krauss, G. L., Betts, T., Abou-Khalil, B. W., Bergey, G. K., YARROW, H., & Miller, A. (2003) · Seizure · doi:10.1016/s1059-1311(03)00139-0 · Cited by 70
Shorvon, S. D. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.1.114 · Cited by 69
Levetiracetam: the first SV2A ligand for the treatment of epilepsy
Klitgaard, H., & Verdru, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.11.1537 · Cited by 68
Shorvon, S. D., & van Rijckevorsel, K. (2002) · PubMed · doi:10.1136/jnnp.72.4.426 · Cited by 67
Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction
Sisodiya, S. M., Sander, J. W. A. S., & Patsalos, P. N. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(01)00309-6 · Cited by 67
Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Privitera, M. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00007.x · Cited by 66
Levetiracetam in progressive myoclonic epilepsy
Crest, C., Dupont, S., Leguern, É., Adam, C., & Baulac, M. (2004) · Neurology · doi:10.1212/01.wnl.0000110193.78872.dd · Cited by 66
Gujjar, A. R., Nandhagopal, R., Jacob, P. C., Al-Hashim, A., Al-Amrani, K., Ganguly, S. S., & Al-Asmi, A. R. (2017) · Seizure · doi:10.1016/j.seizure.2017.05.001 · Cited by 65
Rosenow, F., Schade‐Brittinger, C., Burchardi, N., Bauer, S., Klein, K. M., Weber, Y. G., Lerche, H., Evers, S., Kovac, S., Hallmeyer‐Elgner, S., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301999 · Cited by 64
Brivaracetam: a novel antiepileptic drug for focal-onset seizures
Stephen, L. J., & Brodie, M. J. (2017) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617742081 · Cited by 64
Brivaracetam Disposition in Renal Impairment
Sargentini‐Maier, M. L., Sokalski, A., Boulanger, P., Jacobs, T., & Stockis, A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011431457 · Cited by 62
Brigo, F., Bragazzi, N. L., Nardone, R., & Trinka, E. (2016) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.09.030 · Cited by 61
Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: A systematic review
Zelano, J., & Kumlien, E. (2012) · Seizure · doi:10.1016/j.seizure.2012.01.008 · Cited by 60
Intravenous brivaracetam in status epilepticus: A retrospective single‐center study
Kalss, G., Rohracher, A., Leitinger, M., Pilz, G., Novak, H. F., Neuray, C., Kreidenhuber, R., Höfler, J., Kuchukhidze, G., & Trinka, E. (2018) · Epilepsia · doi:10.1111/epi.14486 · Cited by 59
Rosenfeld, W. E., Benbadis, S. R., Edrich, P., Tassinari, C. A., & Hirsch, É. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.02.016 · Cited by 58
Brivaracetam and carbamazepine interaction in healthy subjects and in vitro
Stockis, A., Chanteux, H., Rosa, M., & Rolan, P. E. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.03.003 · Cited by 58
Stockis, A., Watanabe, S., Rouits, E., Matsuguma, K., & Irie, S. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-14-rg-010 · Cited by 56
Delanty, N., Jones, J. J., & Tonner, F. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03300.x · Cited by 55
Effects of cannabidiol on brivaracetam plasma levels
Klotz, K. A., Hirsch, M., Heers, M., Schulze‐Bonhage, A., & Jacobs, J. (2019) · Epilepsia · doi:10.1111/epi.16071 · Cited by 55
Kälviäinen, R., Genton, P., Andermann, E., Andermann, F., Magaudda, A., Frucht, S. J., Schlit, A., Gerard, D., de la Loge, C., & von Rosenstiel, P. (2016) · Epilepsia · doi:10.1111/epi.13275 · Cited by 53
Borggraefe, I., Bonfert, M., Bast, T., Neubauer, B. A., Schotten, K., Maßmann, K. L., Noachtar, S., Tuxhorn, I., May, T. W., & Heinen, F. (2013) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2013.03.014 · Cited by 52
Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences
Zahnert, F., Krause, K., Immisch, I., Habermehl, L., Gorny, I., Chmielewska, I., Möller, L., Weyand, A. M., Mross, P. M., Wagner, J., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00038 · Cited by 52
Willems, L. M., Bertsche, A., Bösebeck, F., Hornemann, F., Immisch, I., Klein, K. M., Knake, S., Kunz, R., Kurlemann, G., Langenbruch, L. M., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00569 · Cited by 51
Self-citationBrivaracetam Disposition in Mild to Severe Hepatic Impairment
Stockis, A., Sargentini‐Maier, M. L., & Horsmans, Y. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.82 · Cited by 49
Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus
Tai, K., & Truong, D. D. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0788-3 · Cited by 49
Schubert‐Bast, S., Willems, L. M., Kurlemann, G., Knake, S., Müller‐Schlüter, K., Rosenow, F., & Strzelczyk, A. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.10.018 · Cited by 48
Steinhoff, B. J., Somerville, E. R., Paesschen, W. V., Ryvlin, P., & Schelstraete, I. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2007.06.002 · Cited by 47
Self-citationRhee, S., Shin, J.-W., Lee, S., Moon, J., Kim, T., Jung, K., Park, K., Lee, S., Jung, K., Yu, K., et al. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.02.011 · Cited by 47
Stockis, A., Watanabe, S., & Fauchoux, N. (2014) · Epilepsia · doi:10.1111/epi.12535 · Cited by 46
Levetiracetam: a long-term follow-up study of efficacy and safety
Bauer, J. M., Ben‐Menachem, E., Krämer, G., Fryze, W., Silva, S. D., & Trenité, D. G. A. K.-N. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00657.x · Cited by 45
Safdieh, J., & Ulloa, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4844 · Cited by 44
Effect of Gemfibrozil on the Metabolism of Brivaracetam In Vitro and in Human Subjects
Nicolas, J. M., Chanteux, H., Rosa, M., Watanabe, S., & Stockis, A. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045328 · Cited by 44
Stockis, A., Watanabe, S., Scheen, A. J., Tytgat, D., Gerin, B., Rosa, M., Chanteux, H., & Nicolas, J.-M. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.069161 · Cited by 41
Lee, J., Song, H. S., Hwang, Y., Lee, H., Suh, C.-K., & Park, S.-P. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.3.128 · Cited by 40
Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years
Schoemaker, R. C., Wade, J. R., & Stockis, A. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2230-6 · Cited by 40
Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Privitera, M. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.0420s4031.x · Cited by 40
Levetiracetam as add-on therapy in generalised epilepsies
Kumar, S., & Smith, P. E. M. (2003) · Seizure · doi:10.1016/j.seizure.2003.06.001 · Cited by 37
Levetiracetam for people with mental retardation and refractory epilepsy
Kelly, K., Stephen, L. J., & Brodie, M. J. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2004.07.009 · Cited by 37
Zhang, L., Li, S., Li, H., & Zou, X. (2016) · Seizure · doi:10.1016/j.seizure.2016.05.004 · Cited by 37
Wood, M. D., Sands, Z. A., Vandenplas, C., & Gillard, M. (2018) · Epilepsia · doi:10.1111/epi.14532 · Cited by 37
Niquet, J., Suchomelova, L., Thompson, K., Klitgaard, H., Matagne, A., & Wasterlain, C. (2017) · Epilepsia · doi:10.1111/epi.13787 · Cited by 35
Antimyoclonic Action of Piracetam
Obeso, J. A., Artieda, J., Luquín, M. R., Vaamonde, J., & Lage, J. M. M. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198602000-00006 · Cited by 34
Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities
Theochari, E. G., Cock, H. R., Lozsádi, D. A., Galtrey, C. M., Arevalo, J., & Mula, M. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.11.032 · Cited by 34
Stockis, A., & Rolan, P. E. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.187 · Cited by 32
Targeting SV2A for Discovery of Antiepileptic Drugs
Kaminski, R. M., Gillard, M., & Klitgaard, H. (2012) · Jasper's Basic Mechanisms of the Epilepsies · doi:10.1093/med/9780199746545.003.0076 · Cited by 31
The long‐term efficacy and safety of levetiracetam in a tertiary epilepsy centre
Kang, B. S., Moon, H. J., Kim, Y., Lee, S., Jung, K., Chu, K., & Lee, S. K. (2013) · Epileptic Disorders · doi:10.1684/epd.2013.0599 · Cited by 29
Nene, D., Mundlamuri, R. C., Satishchandra, P., Prathyusha, P. V., Nagappa, M., Bindu, P. S., Kenchaiah, R., Saini, J. S., Bharath, R. D., Thennarasu, K., et al. (2019) · Seizure · doi:10.1016/j.seizure.2019.01.015 · Cited by 29
Safety Profile of Levetiracetam
Harden, C. L. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.0420s4036.x · Cited by 28
Assessment of a dose–response relationship of levetiracetam
Meencke, H. ‐., & Buyle, S. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01381.x · Cited by 27
Anderson, G. D., & Saneto, R. P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0268-5 · Cited by 26
Safety profile of levetiracetam
Arroyo, S., & Crawford, P. M. (2003) · Epileptic Disorders · doi:10.1684/j.1950-6945.2003.tb00032.x · Cited by 25
Influence of Comedication on Levetiracetam Pharmacokinetics
Aldaz, A., Alzueta, N., & Viteri, C. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000470 · Cited by 25
Steinhoff, B. J. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615575696 · Cited by 24
Self-citationArnold, S., Badalamenti, V., Diaz, A., Gasalla, T., McShea, C., Whitesides, J., & Fakhoury, T. A. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.02.005 · Cited by 24
Steinhoff, B. J., Staack, A. M., & Wisniewski, I. (2012) · Epileptic Disorders · doi:10.1684/epd.2012.0544 · Cited by 22
Self-citationBrodie, M. J., Fakhoury, T. A., McDonough, B., Colson, A., Stockis, A., Elmoufti, S., & Whitesides, J. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.06.002 · Cited by 22
Profile of brivaracetam and its potential in the treatment of epilepsy
Ferlazzo, E., Russo, E., Mumoli, L., Sueri, C., Gasparini, S., Palleria, C., Labate, A., Gambardella, A., Sarro, G. D., & Aguglia, U. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s60849 · Cited by 20
Evaluation of brivaracetam: a new drug to treat epilepsy
Milovanovic, J. R., Јаnkovic, S., Pejčić, A. V., Milosavljević, M. N., Opančina, V., Radonjić, V., Protrka, Z., & Kostić, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359260 · Cited by 20
Toledo, M., Abraira, L., Mazuela, G., Quintana, M., Cazorla, S., & Santamarina, E. (2019) · Seizure · doi:10.1016/j.seizure.2019.04.021 · Cited by 19
Abolition of Photoparoxysmal Response in Progressive Myoclonus Epilepsy
Paulus, W., Ried, S., Stodieck, S. R. G., & Schmidt, D. (2008) · European Neurology · doi:10.1159/000116700 · Cited by 15
Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures
Friedman, D. J., & French, J. A. (2006) · Neurology · doi:10.1212/01.wnl.0000198500.84481.da · Cited by 12
Steinhoff, B. J., Kurth, C., & Dennig, D. (2012) · Clinical Epileptology · doi:10.1007/s10309-012-0237-7 · Cited by 11
Self-citationAntiepileptic therapy with bromides— historical and actual importance
Steinhoff, B. J. (1992) · Journal of the History of the Neurosciences · doi:10.1080/09647049209525523 · Cited by 10
Self-citationBrivaracetam enters the brain faster than levetiracetam: a PET study in healthy volunteers (P6.233)
Finnema, S. J., Mercier, J., Naganawa, M., Nabulsi, N., Kervyn, S., Henry, S. E., Nicolas, J.-M., Huang, Y. H., Chen, M., Hannestad, J. O., et al. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.p6.233 · Cited by 8
The Expanding SCN8A -Related Epilepsy Phenotype
Poduri, A. (2015) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7511-15.6.333 · Cited by 6
Phenytoin, Valproat, Levetiracetam und Lacosamid im Status epilepticus
Brigo, F., Kalss, G., & Trinka, E. (2018) · Clinical Epileptology · doi:10.1007/s10309-018-0207-9 · Cited by 4
Teaching Neuro Images : Fahr syndrome caused by hypoparathyroidism
Dade, E., Saint-Joy, V., Haynes, N., & Berkowitz, A. L. (2017) · Neurology · doi:10.1212/wnl.0000000000004014 · Cited by 3
Research works printed but not linked: 10
- Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drugs Rev 2005; 11: 169– 182. PMC6741724 16007238 · DOI · Paper page
- Perucca E Baltes E Ledent E. Levetiracetam: absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs) [Abstract] Epilepsia 2000; 41: 150.
- Hannestad J Finnema SJ Mercier J, et al Brivaracetam enters the human brain faster than levetiracetam. Epilepsia 2016; 57(Suppl. 2): 128.
- Lacroix B von Rosenstiel P Sarrgentini-Maier AL. Population pharmacokinetics of brivaracetam in patients with partial epilepsy. Epilepsia 2007; 48(Suppl. 6): 333.
- Otoul C Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures. Poster presented at American Epilepsy Society 69th Annual meeting, 12 4–8, 2015, Philadelphia, PA.
- Detrait E Lecelrcq K Matagne A, et al Protective activity of brivaracetam in the 6Hz model of partial epilepsy: comparison with levetiracetam and older antiepileptic drugs. Epilepsia 2008; 49(Suppl. 7): 1252.
- Steinhoff BJ Sommerville ER Van Paeschen W, et al The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 2007; 76: 6– 14. 17681453 · DOI
- Buck ML. Levetiracetam for the treatment of partial seizures. Pediatric Pharmacoth 2002; 8: 1– 5.
- 10.1345/aph.1A032 · doi:10.1345/aph.1a032 · Paper page
- D’Souza J Johnson M Borghs S. Meta-analysis of non-psychotic behavioral treatment-emergent adverse events in brivaracetam and levetiracetam development programs. Epilepsia 2012; 53(Suppl. 5): 118: abstract P402.
Cited by
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“Although piracetam is a nootropic drug, LEV does not show significant nootropic effects; however, it was evaluated in epilepsy models since piracetam exhibited efficacy in the treatment of photo paroxysmal responses and myoclonus [15].”
BackgroundInfluentialTowards Realizing the Vision of Precision Medicine: AI Based Prediction of Clinical Drug Response
de Jong, J., Cutcutache, I., Page, M., Elmoufti, S., Dilley, C., Fröhlich, H., & Armstrong, M. (2020) · Brain · doi:10.1093/brain/awab108 · Cited by 124
The pharmacological treatment of epilepsy: recent advances and future perspectives
Perucca, E. (2021) · Acta Epileptologica · doi:10.1186/s42494-021-00055-z · Cited by 110
Palliative care and end-of-life care in adults with malignant brain tumors
Koekkoek, J. A. F., van der Meer, P. B., Pace, A., Hertler, C., Harrison, R. A., Leeper, H. E., Forst, D. A., Jalali, R., Oliver, K. R., Philip, J. A. M., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac216 · Cited by 113
Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy
Besag, F., & Vasey, M. J. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00448-0 · Cited by 93
Metadata
- Authors
- Steinhoff, B. J., & Staack, A. M.
- Affiliations
- Diakonie Kork (DE)
- Corresponding author
- Steinhoff, Bernhard J.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 12
- Pages
- 1756286419873518-1756286419873518
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- PMC
- PMC6734620
- OpenAlex
- W2973225802
- Semantic Scholar
- bdff5b0eebcdf5f0c63ceceb24eab6399dc13cbf
- Cited by
- 99
- References
- 144
- Citations by year
- 2026: 17 · 2025: 9 · 2024: 17 · 2023: 12 · 2022: 15 · 2021: 19 · 2020: 8 · 2019: 1
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Neurological Disorders (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- levetiracetam, brivaracetam, antiepileptic drugs, pyrrolidinone derivatives, focal epilepsy, generalized epilepsy, pharmacokinetics, drug interactions, adverse drug reactions, adjunctive therapy, first-line therapy, epilepsy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.